<DOC>
	<DOCNO>NCT00837083</DOCNO>
	<brief_summary>This open label , non-interventional study show efficacy Crestor ( rosuvastatin ) reduction LDL-cholesterol cardiovascular risk parameter patient hypercholesterolemia . Effectiveness evaluate use difference LDL cholesterol level first second visit 12 week .</brief_summary>
	<brief_title>Evaluation CrestorÂ® ( Rosuvastatin ) Daily Practice</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>patient hypercholesterolemia prescribe Crestoraccording physician 's judgement , irrespective inclusion study . treatment statin last 3 month hypersensitivity rosuvastatin ingredient Crestor active liver disease , severe renal insufficiency myopathy predispose risk factor myopathy/ rhabdomyolysis woman childbearing potential use appropriate contraceptive measure , pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>hypercholesterolemia</keyword>
	<keyword>cholesterol</keyword>
	<keyword>LDL-cholesterol</keyword>
	<keyword>rosuvastatin</keyword>
	<keyword>Crestor</keyword>
</DOC>